[18F]fluorodeprenyl-D2 PET can detect and monitor astrogliosis in anti-LGI1-IgG autoimmune encephalitis
To explore whether detecting local astrogliosis using [18F]fluorodeprenyl-D2 ([18F]F-DED) positron-emission-tomography (PET) uncovers and monitors inflammatory lesions in patients with anti-leucine-rich glioma-inactivated 1 antibody (LGI1-ab) associated autoimmune encephalitis (AE). Dynamic [18F]F-DED PET scans (0–60 min post-injection) were obtained from a cohort of 15 LGI1-AE patients, 9 of whom were re-examined during the disease course, and from 15 controls. PET quantification was performed by kinetic modelling with an image derived input function and calculation of simplified standardized uptake values (SUV). [18F]F-DED SUVr (referenced to the straight gyrus) were analyzed for LGl1-AE target regions, compared between baseline and follow-up PET scans, used to investigate asymmetry of the mesial temporal lobe (MTL), and correlated to routine clinical data. Simplified [18F]F-DED PET quantification of the 30–60 min time-frame showed excellent agreement with kinetic modelling of the full dynamic imaging protocol. In LGI1-AE patients, [18F]F-DED SUVr values were significantly increased by 16% in the MTL (p = .002) and by 12% in the cerebellum (p = .014). [18F]F-DED signals in the MTL significantly declined during the course of the disease (mean follow-up time: 15 months, p = .006). MTL asymmetry (> 5%) of [18F]F-DED SUVr was present in 8/15 of LGI1-AE patients compared to 1/15 controls (p < .001) and showed marked decline between baseline and follow-up in LGI1-AE patients. This pilot study shows that [18F]F-DED PET is a promising tool to monitor regional astrogliosis in LGI1-AE patients and may provide a direct read-out of this important aspect of inflammatory disease activity.
Authors
- Gérard N. Bischof (ORCID: https://orcid.org/0000-0002-4366-5171)
- Martin Kerschensteiner (ORCID: https://orcid.org/0000-0003-4898-9383)
- Robert Perneczky (ORCID: https://orcid.org/0000-0003-1981-7435)
- Letizia Vogler (ORCID: https://orcid.org/0000-0001-7139-2345)
- Tania Kümpfel (ORCID: https://orcid.org/0000-0001-7509-5268)
- Lisa Tagnin
- Rudolf Alexander Werner (ORCID: https://orcid.org/0000-0003-3372-6046)
- Boris‐Stephan Rauchmann (ORCID: https://orcid.org/0000-0003-4547-6240)
- Johannes Levin (ORCID: https://orcid.org/0000-0001-5092-4306)
- Matthias Brendel (ORCID: https://orcid.org/0000-0002-9247-2843)
- Johannes Gnörich (ORCID: https://orcid.org/0000-0003-1554-7765)
- Jonathan A. Gernert (ORCID: https://orcid.org/0000-0002-6655-5557)
- F. Thaler
- Sabrina Katzdobler (ORCID: https://orcid.org/0000-0002-3512-5984)
- Hanna Zimmermann (ORCID: https://orcid.org/0000-0002-0276-8051)
- Günter U. Höglinger (ORCID: https://orcid.org/0000-0001-7587-6187)
- Nicolai Franzmeier (ORCID: https://orcid.org/0000-0001-9736-2283)
- Simon Lindner (ORCID: https://orcid.org/0009-0007-4379-4436)
- R. Schaefer
- Laura Sanzo
- Benjamin Kugelmann
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- German Center for Neurodegenerative Diseases (DE)
- LMU Klinikum (DE)
- Munich Cluster for Systems Neurology (DE)
- Imperial College London (GB)
- Ludwig-Maximilians-Universität München (DE)
- University of Gothenburg (SE)
- University of Sheffield (GB)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1007/s00259-025-07531-5
- Citations
- 1
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Deutsche Forschungsgemeinschaft
- Fritz Thyssen Stiftung